RTS Life Science ‘Hatch’ new inhaler and tablet testing group
In the wake of the acquisition of Massachusetts-based Hatch Life Science LLC earlier in the year, RTS Life Science’s UK team, along with researchers from the US, will work together to create a new range of dose content uniformity, analytical development, and dissolution testing systems, in both quality control and batch release testing environments.
With over 30 of these systems installed on both sides of the pond, and a network of experienced researchers in the field of tablet and inhaler testing automation, Martin Schwalm, President of UK-based RTS Life Science told in-PharmaTechnologist, “the formation of the group enables us to better serve and support the broad needs of our pharmaceutical development and QC customers on both sides of the Atlantic.”
Tailor made solutions
Taking this into account, Schwalm is upbeat about the custom solutions RTS Life Science offers to clients from pharma and biotech organisations, which he says are “tailored to client specific applications in terms of device, testing and throughput requirements,” and designed for numerous applications from discovery to scale-up and production.
Alongside this, RTS has addressed its market with a vast standard range of products, including its RTS SolidPrep for benchtop tablet homogenisation; the RTS PrepStation, an automated sample preparation system; the RTS Release, an automated spectroscopy based solid dose testing system; and the RTS LabEye video monitoring system.
This all contributes to RTS Life Science’s wider plan to “develop, sell, and support a range of automated testing solutions to pharma clients in Europe and the US,” said Schwalm.
Teaming with Hall Analytical
Forming the testing unit follows on from a deal struck in 2009, when the Manchester-based supplier of automated sample management and pharmaceutical testing systems teamed up with Hall Analytical to provide drug developers with inhaler testing and development consulting services on a contractual basis.
